Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519938 | 0.97 | GBA1 (0.43) | GBA1CALM1POLBCCR3SLC6A2 | |
| SCHEMBL6523887 | 0.83 | GBA1 (0.37) | GBA1CCR3 | |
| SCHEMBL1930265 | 0.80 | GBA1 (0.47) | GBA1POLBCCR3SLC6A2SLC6A4 | |
| SCHEMBL1200483 | 0.80 | GBA1 (0.42) | GBA1CALM1POLBCCR3 | |
| SCHEMBL1929149 | 0.75 | POLB (0.43) | GBA1POLBCCR3SLC6A2SLC6A4 | |
| SCHEMBL31621835 | 0.73 | SIGMAR1 (0.48) | GBA1 | |
| SCHEMBL1928709 | 0.73 | POLB (0.46) | GBA1POLBCCR3 | |
| SCHEMBL9379151 | 0.73 | GBA1 (0.41) | GBA1CALM1POLBCCR3 | |
| SCHEMBL7812033 | 0.72 | GBA1 (0.54) | GBA1CCR3 | |
| SCHEMBL2027845 | 0.70 | GBA1 (0.71) | GBA1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980387-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2019-04-19 | — | — | CN | claimed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | claimed |
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| WO-2000075116-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-12-14 | — | — | WO | claimed |
| CN-105980387-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-107690281-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2018-02-13 | — | — | CN | disclosed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | disclosed |
| CN-105980387-A | Serine/threonine kinase inhibitors | 阵列生物制药公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-104387303-B | The asymmetric over cure compound of aryl-aryl, aryl-alkyl, alkyl-alkyl and synthetic method thereof | 华东师范大学 | 2016-06-29 | — | — | CN | disclosed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | disclosed |
| CN-104387303-A | Aryl-aryl, aryl-alkyl and alkyl-alkyl asymmetric persulfides and synthesis method thereof | UNIV EAST CHINA NORMAL | 2015-03-04 | — | — | CN | disclosed |
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2000075116-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | GBA1 2306/4885CALM1 528/4885POLB 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.